Trial · NCT00920140
Results by group197
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 197
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) by Dose | GSK1120212 <2 mg OD | Any AE | 6 | Participants | |
| Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) by Dose | GSK1120212 2 mg OD | Any AE | 91 | Participants | |
| Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) by Dose | GSK1120212 <2 mg OD | Any SAE | 2 | Participants | |
| Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) by Dose | GSK1120212 2 mg OD | Any SAE | 64 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 <2 mg OD | Hemoglobin (Low), Grade 3, n=6, 91 | 3 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 2 mg OD | Hemoglobin (Low), Grade 3, n=6, 91 | 28 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 <2 mg OD | Hemoglobin (Low), Grade 4, n=6, 91 | 0 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 2 mg OD | Hemoglobin (Low), Grade 4, n=6, 91 | 7 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 <2 mg OD | INR (High), Grade 3, n=6, 75 | 0 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 2 mg OD | INR (High), Grade 3, n=6, 75 | 0 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 <2 mg OD | INR (High), Grade 4, n=6, 75 | 0 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 2 mg OD | INR (High), Grade 4, n=6, 75 | 0 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 <2 mg OD | Lymphocytes (Low), Grade 3, n=6, 90 | 0 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 2 mg OD | Lymphocytes (Low), Grade 3, n=6, 90 | 12 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 <2 mg OD | Lymphocytes (Low), Grade 4, n=6, 90 | 0 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 2 mg OD | Lymphocytes (Low), Grade 4, n=6, 90 | 7 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 <2 mg OD | Total Neutrophils (Low), Grade 3, n=6, 89 | 1 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 2 mg OD | Total Neutrophils (Low), Grade 3, n=6, 89 | 4 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 <2 mg OD | Total Neutrophils (Low), Grade 4, n=6, 89 | 1 | Participants | |
| Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose | GSK1120212 2 mg OD | Total Neutrophils (Low), Grade 4, n=6, 89 | 21 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00920140/results